Liang-Liang Shi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Liang-Liang Shi has a total of 153 co-authors. Here are the top co-authors by number of shared publications:
- Kunyu Yang
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
14 shared publications - Jing Huang
Huazhong University of Science and Technology 2 Cancer Center, Union Hospital, Tongji Medical College Wuhan, China
12 shared publications - Xiao-Hua Hong
Huazhong University of Science and Technology 2 Cancer Center, Union Hospital, Tongji Medical College Wuhan, China
12 shared publications - Zhan-Jie Zhang
Huazhong University of Science and Technology 2 Cancer Center, Union Hospital, Tongji Medical College Wuhan, China
12 shared publications - Cheng Xu
Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou 510060, China
11 shared publications - Fan Zhang
Fifth Affiliated Hospital of Sun Yat-sen University 10 Zhuhai
11 shared publications
Latest Publications
- 10 September 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF9
Response-Adapted Surgery after Neoadjuvant Immunochemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma (REMATCH): A Single-Arm Phase II Trial
Purpose: We assessed the feasibility and efficacy of a response-adapted surgical strategy in patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) achieving major tumor regression after neoadjuvant immunochemotherapy (NAICT). Patients and Methods: This phase II, single-arm, prospective trial enrolled patients with resectable, human papillomavirus–negative stage III to IVA LA-HNSCC. All received three cycles of NAICT (penpulimab, nab-paclitaxel, and cisplatin). Pre–cycle 3 imaging and laryngoscopy guided surgery: Patients with ≥50% primary tumor regression underwent reduced-volume surgery (RVS); those with <50% regression received standard-volume surgery (SVS). All received risk-adapted adjuvant radiotherapy. The primary endpoint was 2-year disease-free survival (DFS). Results: Fifty patients completed NAICT, with an objective response rate of 94% [95% confidence interval (CI), 84%–99%]. At a median follow-up of 34.0 months (IQR, 30.1–39.5), the 2-year DFS for the per-protocol cohort was 83% (95% CI, 69%–91%). The RVS group (n = 42) achieved a 2-year DFS of 90% (95% CI, 77%–96%) with 100% laryngeal preservation in laryngeal/hypopharyngeal cancers, whereas the SVS group (n = 5) had a 2-year DFS of 20% (95% CI, 0.8%–58%). Grade 3 adverse events (AE) occurred in 16% of patients related to NAICT and in 15% related to surgery; there were no grade 4 or 5 AEs. At 9 months after radiotherapy, most quality-of-life scores improved or stabilized compared with baseline. Conclusions: The REMATCH trial provides the first prospective evidence that a response-adapted surgical strategy after NAICT is feasible. Patients achieving ≥50% primary tumor regression derived promising survival and universal laryngeal preservation. These findings support the initiation of phase III randomized trials to validate this de-escalation strategy.
- 10 September 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF9
Response-Adapted Surgery after Neoadjuvant Immunochemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma (REMATCH): A Single-Arm Phase II Trial
Purpose: We assessed the feasibility and efficacy of a response-adapted surgical strategy in patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) achieving major tumor regression after neoadjuvant immunochemotherapy (NAICT). Patients and Methods: This phase II, single-arm, prospective trial enrolled patients with resectable, human papillomavirus–negative stage III to IVA LA-HNSCC. All received three cycles of NAICT (penpulimab, nab-paclitaxel, and cisplatin). Pre–cycle 3 imaging and laryngoscopy guided surgery: Patients with ≥50% primary tumor regression underwent reduced-volume surgery (RVS); those with <50% regression received standard-volume surgery (SVS). All received risk-adapted adjuvant radiotherapy. The primary endpoint was 2-year disease-free survival (DFS). Results: Fifty patients completed NAICT, with an objective response rate of 94% [95% confidence interval (CI), 84%–99%]. At a median follow-up of 34.0 months (IQR, 30.1–39.5), the 2-year DFS for the per-protocol cohort was 83% (95% CI, 69%–91%). The RVS group (n = 42) achieved a 2-year DFS of 90% (95% CI, 77%–96%) with 100% laryngeal preservation in laryngeal/hypopharyngeal cancers, whereas the SVS group (n = 5) had a 2-year DFS of 20% (95% CI, 0.8%–58%). Grade 3 adverse events (AE) occurred in 16% of patients related to NAICT and in 15% related to surgery; there were no grade 4 or 5 AEs. At 9 months after radiotherapy, most quality-of-life scores improved or stabilized compared with baseline. Conclusions: The REMATCH trial provides the first prospective evidence that a response-adapted surgical strategy after NAICT is feasible. Patients achieving ≥50% primary tumor regression derived promising survival and universal laryngeal preservation. These findings support the initiation of phase III randomized trials to validate this de-escalation strategy.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data S1 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
This file contains the protocol and statistical analysis plan.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S1 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
This file contains the protocol and statistical analysis plan.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
Figure S2 shows percentage change from baseline in target lesion size over time for individual patients in the TPGC cohort.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
Figure S2 shows percentage change from baseline in target lesion size over time for individual patients in the TPGC cohort.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
Figure S3 depicts Kaplan–Meier curves of progression-free survival according to PD-L1 expression status in the TPGC cohort.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
Figure S3 depicts Kaplan–Meier curves of progression-free survival according to PD-L1 expression status in the TPGC cohort.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
Figure S4 shows cell-free EBV DNA dynamics of the TP cohort.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
Figure S4 shows cell-free EBV DNA dynamics of the TP cohort.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
Figure S5 shows cell-free EBV DNA dynamics of the TPGC cohort.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
Figure S5 shows cell-free EBV DNA dynamics of the TPGC cohort.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
Figure S6 depicts Kaplan–Meier curves of progression-free survival according to EBV DNA dynamics-based group in patients from the two cohorts.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
Figure S6 depicts Kaplan–Meier curves of progression-free survival according to EBV DNA dynamics-based group in patients from the two cohorts.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
Table S1 shows the representativeness of study participants.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
Table S1 shows the representativeness of study participants.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
Table S3 summarizes clinical trials that explore PD-1 blockade combined with GP chemotherapy in R/M NPC.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
Table S3 summarizes clinical trials that explore PD-1 blockade combined with GP chemotherapy in R/M NPC.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
Table S2 details the information of recruitment sites.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
Table S2 details the information of recruitment sites.